The Rudolstadt-headquartered firm said that Prosonix’ unique crystallisation approach produces optimally-sized active pharmaceutical ingredient (API) particles direct from solution, bypassing destructive processes like milling and micronization that are used in traditional manufacture.
Aeropharm is targeting the lucrative inhaled drug market, which is expected to be worth $38bn in 2012. In particular the firm is focused on the development of “difficult-to-make” generic products.